ClinicalTrials.gg
TerminatedNCT04601467PASSIVATEUpdated Apr 27, 2025

PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE

A Phase 2 interventional study of AZD5718 and Placebo in Acute Coronary Syndrome, sponsored by National University Heart Centre, Singapore. Terminated at 8 sites in 2 countries. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by National University Heart Centre, Singapore · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated early on 14th September 2023 by the main funding company because of financial futility. We were able to enroll 243 of the initial planned 360 participants and randomised 209 participants of the intial planned 286.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Acute Coronary Syndrome with a site in Singapore — 2 open to participants now, 3 under way, 1 of them phase 3. Acute Coronary Syndrome · Singapore.

Enrollment
12th of 16
243 · median 1,718
Started
2021
the only one that year
Phase 2
Only one
of the 18
Registered
13th of 18
by date
Lead sponsor
3 of 18
National University Heart Centre, Singapore

Among the 18 studies in Acute Coronary Syndrome with a site in Singapore, this one is the 12th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2021, is the only one in phase 2, and was the 13th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

2 of the 18 studies in Acute Coronary Syndrome with a site in Singapore are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Acute Coronary Syndrome with a site in Singapore, or all of them as a file.
02

Study summary

This is a multi-center study conducted at 8 sites in 2 countries (Singapore, New Zealand). Patients with an acute myocardial infarction (AMI) were randomized in a ratio of 1:1 ratio to receive AZD5718 (Atuliflapon) 125 mg or placebo for 12 months to assess the efficacy of AZD5718 to prevent coronary plaque progression as measured on serial computer tomographic coronary angiography.

Read the detailed description

PASSIVATE is a randomized, double-blind, placebo-controlled Phase IIa trial that investigates how 12 months of treatment with AZD5718 modifies coronary plaque volume. Patients with recent STEMI or NSTEMI will receive an additional oral dose of AZD5718 (or placebo) once daily to standard clinical care for 12 months. The primary hypothesis being tested in PASSIVATE is that 12 months of treatment with AZD5718 attenuates the progression of non-calcified plaque (NCP) volume on serial computed tomography coronary angiography (CTCA) studies.

Patients who gave consent (within 60 days after their index event) will undergo a CTCA scan and start treatment (AZD5718 or Placebo). The treatment duration will be 12 months. During the treatment period, patients will come to the clinic for follow-ups. At 12 months (end treatment), the patients will undergo their 2nd CTCA scan. A follow-up visit will be performed 4 weeks after the last dose in order to ensure the safety and well-being of the patients.

03

Conditions studied

  • Acute Coronary Syndrome

Keywords

  • Acute Myocardial Infarction
  • Computed Tomography Coronary Angiography
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • hospitalised for STEMI or non-STEMI, as defined by the 4th universal definition of MI
  • underwent coronary angiography during the index hospitalisation showing at least one epicardial coronary artery with ≥50% stenosis and a 2nd epicardial coronary artery with ≥20% stenosis on the coronary angiogram
  • (BMI) ≥18 to ≤40 kg/m2
  • White Blood Cell count ≥ 7.0 X 103/uL during admission

Exclusion criteria

Exclusion Criteria:

  • Prior coronary artery bypass grafting (CABG)
  • CABG planned within 12 months of admission
  • Known history of drug or alcohol abuse within 5 years of screening
  • History of associated with other medications that required discontinuation of that medication
  • Congenital long QT syndrome
  • Systolic blood pressure persistently \<90 mm Hg or HR\<40 beats per minute at time of enrolment
  • >2 x , cirrhosis, recent hepatitis, or positive screening test for (hepatitis B surface antigen) or other viral hepatitis
  • Uncontrolled Type 1 or Type 2 DM defined as >10% or 74.9 mmol/mol (by IFCC)
  • Any planned coronary revascularisation, valve surgery, or cardiac resynchronisation within 7 months after randomisation
  • Any concomitant medications known to be associated with Torsades de Pointes or potent inducers of cytochrome P450 3A4 ()
  • Planned treatment with zileuton, leukotriene receptor antagonists (e.g., montelukast) during trial
  • Participated in another interventional clinical study with an pharmaceutical product during the last 3 months
  • Known to drugs with a similar chemical structure or class of study drugs or any of the of the product
  • Known conditions that either increase the risk of performing the CT or make the procedure technically impractical
  • No severe asthma attack that require emergency treatment or hospitalisation in the past 6 months
  • Had severe course of COVID-19 (extracorporeal membrane oxygenation, mechanically ventilated), and/or had a confirmed case of COVID-19 within 4 weeks of Screening Visit
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
243 participants (actual)

Study arms

  • Experimental
    AZD5718

    Patients will receive once daily oral dose of AZD5718 for 12 months

    Drug: AZD5718

  • Placebo comparator
    Placebo

    Patients will receive once daily oral dose of placebo matched to AZD5718 for 12 months

    Drug: Placebo

Interventions

  • Oral dose of AZD5718 (tablet) once daily for 12 months

  • DrugPlacebo

    Oral dose of matching placebo (tablet) once daily for 12 months

06

What researchers measure

Primary outcomes

  1. Change in noncalcified coronary artery plaque volume (NCPV)

    Percent change in NCPV (in mm3), as assessed by CT coronary angiography, from baseline (before treatment) to after 12-month of treatment

    Time frame: Baseline (before treatment) and after 12 months of treatment

Secondary outcomes

  1. Change in CT peri vascular (coronary) adipose tissue (PVAT)

    To assess whether AZD5718 reduces coronary inflammation

    Time frame: Baseline (before treatment) and after 12 months of treatment

  2. Change in total plaque volume (mm3)

    Percent change in total plaque volume (in mm3), as assessed by CT coronary angiography, from baseline (before treatment) to after 12-month of treatment

    Time frame: Baseline (before treatment) and after 12 months of treatment

  3. Echocardiographic assessment: Change in left ventricular ejection fraction (LVEF)

    Percent change in LVEF (%), as assessed by 2D echocardiography, from baseline (before treatment) to after 12-month of treatment

    Time frame: Baseline (before treatment) and after 12 months of treatment

  4. Change in levels of urinary LTE4 (u-LTE4)

    To assess the pharmacodynamics (PD) effect of AZD5718 by assessment of u-LTE4 in AMI patients

    Time frame: 12 months

Other outcomes

  1. Change in low attenuation plaque burden

    Percent change in low attenuation (\<30 HU) plaque volume (mm3), as assessed by CT coronary angiography, from baseline (before treatment) to after 12-month of treatment

    Time frame: Baseline (before treatment) and after 12 months of treatment

  2. Change in plasma hs-CRP concentration

    To assess the changes in circulating hs-CRP concentrations from baseline (before treatment) to after 12-month of treatment

    Time frame: Baseline (before treatment) and after 12 months of treatment

  3. Echocardiographic assessment: Change in LV global longitudinal strain

    Percent change in LV global longitudinal strain, as assessed by 2D echocardiography, from baseline (before treatment) to after 12-month of treatment

    Time frame: Baseline (before treatment) and after 12 months of treatment

  4. Echocardiographic assessment: Change in global circumferential strain

    Percent change in global circumferential strain, as assessed by 2D echocardiography, from baseline (before treatment) to after 12-month of treatment

    Time frame: Baseline (before treatment) and after 12 months of treatment

  5. Echocardiographic assessment: Change in longitudinal early diastolic strain rate

    Percent change in longitudinal early diastolic strain rate, as assessed by 2D echocardiography, from baseline (before treatment) to after 12-month of treatment

    Time frame: Baseline (before treatment) and after 12 months of treatment

07

Study locations

8 sites
  • North Shore Hospital
    Auckland, New Zealand
  • Christchurch Heart Institute (CHI)
    Christchurch, New Zealand
  • Changi General Hospital (CGH)
    Singapore, Singapore
  • Khoo Teck Puat Hospital (KTPH)
    Singapore, Singapore
  • National Heart Centre Singapore (NHCS)
    Singapore, Singapore
  • National University Heart Centre, Singapore (NUHCS)
    Singapore, Singapore
  • Ng Teng Fong General Hospital (NTFGH)
    Singapore, Singapore
  • Tan Tock Seng Hospital (TTSH)
    Singapore, Singapore
08

References and documents

Publications

  • Ericsson H, Nelander K, Lagerstrom-Fermer M, Balendran C, Bhat M, Chialda L, Gan LM, Heijer M, Kjaer M, Lambert J, Lindstedt EL, Forsberg GB, Whatling C, Skrtic S. Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor. Clin Transl Sci. 2018 May;11(3):330-338. doi: 10.1111/cts.12546. Epub 2018 Mar 8. PubMed 29517132 ↗
  • Pettersen D, Broddefalk J, Emtenas H, Hayes MA, Lemurell M, Swanson M, Ulander J, Whatling C, Amilon C, Ericsson H, Westin Eriksson A, Granberg K, Plowright AT, Shamovsky I, Dellsen A, Sundqvist M, Nagard M, Lindstedt EL. Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease. J Med Chem. 2019 May 9;62(9):4312-4324. doi: 10.1021/acs.jmedchem.8b02004. Epub 2019 Mar 26. PubMed 30869888 ↗

Individual participant data

Plan to share: Yes — We will share anonmyised IPD upon reasonable request from academic investigators employed by universities and/or healthcare organisations to the study PIs.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Start date and end date will be specified upon publication of the primary trial results

Access criteria: Only investigators employed by universities or healthcare organisations upon reasonable request to the study PIs.

Data sharing details ↗ · medicine.nus.edu.sg

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in May 2024, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2020
First posted
Oct 23, 2020
StartActual
Jul 12, 2021
Primary completionActual
May 27, 2024
CompletionActual
Aug 14, 2024
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04601467
Lead sponsor
National University Heart Centre, Singapore
Collaborators
AstraZeneca, University of Otago
Responsible party
Mark Chan (Associate Professor, National University Heart Centre, Singapore) — Principal investigator
First posted
Oct 23, 2020
Start date
Jul 12, 2021
Primary completion
May 27, 2024
Completion
Aug 14, 2024
Last update
Apr 27, 2025

Study contacts

Mark Chan
principal investigator · National University Heart Centre, Singapore
Derek Hausenloy
principal investigator · National Heart Centre Singapore
A. Mark Richards
study chair · National University Heart Centre, Singapore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD5718

Start the discussion